PTC Therapeutics has shared a community letter updating on the company’s activities to bring ataluren (Translarna) to US patients with nonsense mutations.

PPMD will host a community webinar with PTC on Friday, December 9th at 12:30 PM ET to discuss this latest update and answer questions. Register to join us.

Click here to read PTC’s letter to the Duchenne community.